T2DM Care Flashcards
(81 cards)
What is T2DM?
Insulin is secreted but not enough to overcome insulin resistance
What increased T2DM risk?
Obesity
Age
Family Hx
Gestational diabetes
Ethnicity
HTN
What are the presenting features?
NOT usually weight loss
No ketonuria
Onset over months
What is the fasting plasma glucose diagnosis?
> 7mmol/L
What is the 2hrs post-prandial glucose diagnosis?
> 11mmol/L
What is the HbA1c diagnosis?
> 48mmol/mol
What should diet be like?
Eat wide range of foods - fruit, veg + starchy foods
Keep sugar + fat to minimum
Do NOT skip meals
How much exercise?
30mins/day 5 days/week
What education is available?
DESMOND/XPERT
What is DESMOND/XPERT?
Prepare individuals to cope with disease
Help to make informed decisions about care
Help patients make behavioural changes
What are the benefits of weight loss?
Decreased insulin requirement
Decreased diabetes risk
Increase HDL
Decreased LDL, cholesterol + triglycerides
Decreased BP
What are the 3 treatment targets?
Lipids
BP
Blood glucose
What are the microvascular complications?
Cognitive impairment
Retinopathy
Neuropathy
Diabetic foot
Sexual dysfunction
What are the macrovascular complications?
Cerebrovascular disease
Coronary heart disease
Peripheral vascular disease
What is monotherapy?
Lifestyle management + metformin
What is dual therapy?
Lifestyle management + metformin + additional agent
What is triple therapy?
Lifestyle management + metformin + 2 additional agents
What is the MoA for Sulphonylureas + Meglitinides?
Stimulate pancreas + increase insulin production
What is the MoA for Biguanides?
Act on liver + cells to decrease glucose production
What is the MoA for Thiazolidinediones?
Act on liver + cells to reduce insulin resistance
What is the MoA for alpha-glucosidase inhibitors?
Acts in the gut to slow absorption of sucrose/starch
What is the MoA for DDP4-inhibitors?
Acts on pancreas + brain to increase the effects of incretin
What is the MoA for GLP-1 agonists?
Acts on pancreas + brain to increase the effects of incretin
What is the MoA for SGLT-2 inhibitors?
Acts in the proximal tubules of nephrons in kidney to inhibit sodium-glucose co-transporter 2 leading to increased glucose excretion